Predictive model for treatment outcomes of peripheral T-cell lymphoma, not otherwise specified, in Taiwanese patients
Purpose: We aimed to explore the clinical outcomes and prognostic factors for PTCL-NOS patients in the real world. Methods: Clinical data were retrospectively collected from adult patients with PTCL-NOS treated at a single center in Taiwan. Results: 104 PTCL-NOS patients with a median age of 53.0 ye...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-02-01
|
| Series: | Journal of the Formosan Medical Association |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0929664623002887 |
| _version_ | 1797292943131803648 |
|---|---|
| author | Ning-Chun Chen Hung Chang Ming-Chung Kuo Tung-Liang Lin Lee-Yung Shih Wen-Yu Chuang Hsiao-Wen Kao |
| author_facet | Ning-Chun Chen Hung Chang Ming-Chung Kuo Tung-Liang Lin Lee-Yung Shih Wen-Yu Chuang Hsiao-Wen Kao |
| author_sort | Ning-Chun Chen |
| collection | DOAJ |
| description | Purpose: We aimed to explore the clinical outcomes and prognostic factors for PTCL-NOS patients in the real world. Methods: Clinical data were retrospectively collected from adult patients with PTCL-NOS treated at a single center in Taiwan. Results: 104 PTCL-NOS patients with a median age of 53.0 years were enrolled. Patients with the International Prognostic Index (IPI) or prognostic index for peripheral T-cell lymphoma (PIT) scores of zero had a longer overall survival (OS) and progression free survival (PFS), while patients with IPI or PIT scores ≥1 did poorly. For patients who are eligible for transplantation, the use of pralatrexate as salvage chemotherapy has shown better OS (2-year OS 83.3% vs. 24.4%, P = 0.011) compared to patients who did not. By multivariate analysis, age >60 years, male, B symptoms, ECOG >1, lung involvement, and thrombocytopenia were independent adverse factors for OS. Incorporating factors in multivariate analysis, we established a novel predictive index for PTCL-NOS which efficiently stratifies patients into low (0–1 factor), intermediate-1 (2 factors), intermediate-2 (3 factors), and high risk (4–6 factors) groups with 2-year OS rates of 81.5%, 32.9%, 8.8%, and 0%, respectively (P < 0.001). Conclusion: PTCL-NOS patients have a dismal prognosis in Taiwan. Novel agents may improve the outcomes of PTCL-NOS patients. The usefulness of the novel prognostic index for PTCL-NOS needs further validation. |
| first_indexed | 2024-03-07T20:04:46Z |
| format | Article |
| id | doaj.art-22db4fca0669434ab6213c8cf3e67e0e |
| institution | Directory Open Access Journal |
| issn | 0929-6646 |
| language | English |
| last_indexed | 2024-03-07T20:04:46Z |
| publishDate | 2024-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of the Formosan Medical Association |
| spelling | doaj.art-22db4fca0669434ab6213c8cf3e67e0e2024-02-28T05:12:47ZengElsevierJournal of the Formosan Medical Association0929-66462024-02-011232188197Predictive model for treatment outcomes of peripheral T-cell lymphoma, not otherwise specified, in Taiwanese patientsNing-Chun Chen0Hung Chang1Ming-Chung Kuo2Tung-Liang Lin3Lee-Yung Shih4Wen-Yu Chuang5Hsiao-Wen Kao6Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, TaiwanDivision of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taiwan; College of Medicine, Chang Gung University, Taoyuan, TaiwanDivision of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taiwan; College of Medicine, Chang Gung University, Taoyuan, TaiwanDivision of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, TaiwanDivision of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taiwan; College of Medicine, Chang Gung University, Taoyuan, TaiwanCollege of Medicine, Chang Gung University, Taoyuan, Taiwan; Department of Anatomic Pathology, Chang Gung Memorial Hospital at Linkou, TaiwanDivision of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taiwan; Corresponding author.Purpose: We aimed to explore the clinical outcomes and prognostic factors for PTCL-NOS patients in the real world. Methods: Clinical data were retrospectively collected from adult patients with PTCL-NOS treated at a single center in Taiwan. Results: 104 PTCL-NOS patients with a median age of 53.0 years were enrolled. Patients with the International Prognostic Index (IPI) or prognostic index for peripheral T-cell lymphoma (PIT) scores of zero had a longer overall survival (OS) and progression free survival (PFS), while patients with IPI or PIT scores ≥1 did poorly. For patients who are eligible for transplantation, the use of pralatrexate as salvage chemotherapy has shown better OS (2-year OS 83.3% vs. 24.4%, P = 0.011) compared to patients who did not. By multivariate analysis, age >60 years, male, B symptoms, ECOG >1, lung involvement, and thrombocytopenia were independent adverse factors for OS. Incorporating factors in multivariate analysis, we established a novel predictive index for PTCL-NOS which efficiently stratifies patients into low (0–1 factor), intermediate-1 (2 factors), intermediate-2 (3 factors), and high risk (4–6 factors) groups with 2-year OS rates of 81.5%, 32.9%, 8.8%, and 0%, respectively (P < 0.001). Conclusion: PTCL-NOS patients have a dismal prognosis in Taiwan. Novel agents may improve the outcomes of PTCL-NOS patients. The usefulness of the novel prognostic index for PTCL-NOS needs further validation.http://www.sciencedirect.com/science/article/pii/S0929664623002887ChemotherapyOutcomePeripheral T-cell lymphoma-not otherwise specifiedPralatrexatePrognostic index |
| spellingShingle | Ning-Chun Chen Hung Chang Ming-Chung Kuo Tung-Liang Lin Lee-Yung Shih Wen-Yu Chuang Hsiao-Wen Kao Predictive model for treatment outcomes of peripheral T-cell lymphoma, not otherwise specified, in Taiwanese patients Journal of the Formosan Medical Association Chemotherapy Outcome Peripheral T-cell lymphoma-not otherwise specified Pralatrexate Prognostic index |
| title | Predictive model for treatment outcomes of peripheral T-cell lymphoma, not otherwise specified, in Taiwanese patients |
| title_full | Predictive model for treatment outcomes of peripheral T-cell lymphoma, not otherwise specified, in Taiwanese patients |
| title_fullStr | Predictive model for treatment outcomes of peripheral T-cell lymphoma, not otherwise specified, in Taiwanese patients |
| title_full_unstemmed | Predictive model for treatment outcomes of peripheral T-cell lymphoma, not otherwise specified, in Taiwanese patients |
| title_short | Predictive model for treatment outcomes of peripheral T-cell lymphoma, not otherwise specified, in Taiwanese patients |
| title_sort | predictive model for treatment outcomes of peripheral t cell lymphoma not otherwise specified in taiwanese patients |
| topic | Chemotherapy Outcome Peripheral T-cell lymphoma-not otherwise specified Pralatrexate Prognostic index |
| url | http://www.sciencedirect.com/science/article/pii/S0929664623002887 |
| work_keys_str_mv | AT ningchunchen predictivemodelfortreatmentoutcomesofperipheraltcelllymphomanototherwisespecifiedintaiwanesepatients AT hungchang predictivemodelfortreatmentoutcomesofperipheraltcelllymphomanototherwisespecifiedintaiwanesepatients AT mingchungkuo predictivemodelfortreatmentoutcomesofperipheraltcelllymphomanototherwisespecifiedintaiwanesepatients AT tunglianglin predictivemodelfortreatmentoutcomesofperipheraltcelllymphomanototherwisespecifiedintaiwanesepatients AT leeyungshih predictivemodelfortreatmentoutcomesofperipheraltcelllymphomanototherwisespecifiedintaiwanesepatients AT wenyuchuang predictivemodelfortreatmentoutcomesofperipheraltcelllymphomanototherwisespecifiedintaiwanesepatients AT hsiaowenkao predictivemodelfortreatmentoutcomesofperipheraltcelllymphomanototherwisespecifiedintaiwanesepatients |